Purine metabolism: a pan-cancer metabolic dysregulation across circulation and tissues
M. C. Yu(China Pharmaceutical University), Wei Zhu(Ministry of Education of the People's Republic of China), Yang Dou(Chinese Academy of Sciences), Jing Xu(Shenzhen University), Danxia Zhu(Soochow University), Minmin Cao, Jiye Aa(China Pharmaceutical University), Guangji Wang(China Pharmaceutical University), Cheng Liu(Nanjing Drum Tower Hospital), Tongshan Wang(Nanjing Medical University)
Cited by 4
Related Papers
Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway
|Annals of the Rheumatic Diseases|2011|412
Interferon and Biologic Signatures in Dermatomyositis Skin: Specificity and Heterogeneity across Diseases
|PLoS ONE|2012|196
Orally Administered Berberine Modulates Hepatic Lipid Metabolism by Altering Microbial Bile Acid Metabolism and the Intestinal FXR Signaling Pathway
|Molecular Pharmacology|2016|196
A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients
|Annals of the Rheumatic Diseases|2013|168
The Antihyperglycaemic Activity of Berberine Arises from a Decrease of Glucose Absorption
|Planta Medica|2003|137